Atlas Trials

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Clinical trial NCT02436668 · COMPLETED

Trial details

NCT number
NCT02436668
Sponsor
Pharmacyclics LLC.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Metastatic Pancreatic Adenocarcinoma
Start date
2015-05-01
Primary completion
2018-10-01
Enrollment
430

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.